"The new facilities will enable us to optimise our operations and also place us at the heart of the exciting new biomedical hub being formed in Tampere for regenerative medicine"
Chip-Man Technologies has moved to new 270 square metre purpose-built facilities as evaluations of its Cell-IQ systems biology platform begin across Europe.
According to Pekka Sillanaukee, chairman, the company is now entering an exciting phase of development: "Cell-IQ generated a vast amount of interest following its recent launch at DDT Europe in London.
"We are now releasing units across Europe for evaluation as the first stage in our drive to become a global player in the $500 million cell biology market.
"The new facilities will enable us to optimise our operations and also place us at the heart of the exciting new biomedical hub being formed in Tampere for regenerative medicine".
To support these efforts Chip-Man has also recruited Andy Higgs as UK sales manager.
He will focus on addressing the growing interest in pharmaceutical and cosmetic companies in using Cell-IQ for preclinical work.
Cell-IQ is said to represent a major breakthrough in cell analysis by enabling real time monitoring of all morphological and physiological changes in cell lines, primary cells, co cultures and monolayer tissue models.
Cell-IQ achieves this by using artificial intelligence (AI) to control novel optics that automatically monitor and follow all the cells in a culture individually.
Through AI, the Cell-IQ software 'learns' to recognise and record cellular change and to output these results as real time moving images and simple multi-parameter graphics.
"Most importantly incorporating AI has removed the need for expensive and labour-intensive traditional end point kits, labels or dyes" says CEO Juha Korpinen.
"Cell-IQ simply translates all the events from a continuous culture experiment into easily understood graphics.
"In addition it stores the recorded images for later interrogation thus reducing the need for repeated costly experimentation."
